NCT01802320 2019-09-20
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
9 trialsNCT01243762 2018-08-16
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01783171 2017-08-22
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT01425879 2016-06-17
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01260701 2016-01-18
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01186705 2015-11-18
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01239355 2015-10-05
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01859182 2014-09-09
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01705340 2013-09-30
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Terminated